Luciana C.C. Leite, is Senior Researcher at the Vaccine Development Laboratory, Butantan Institute. She specializes in molecular biology applied to vaccine development, mainly using recombinant BCG technology and has participated in several of the Brazilian genomic projects with over 150 papers published and several patents. The first product developed, a recombinant BCG strain for improved bladder cancer treatment has the Phase I clinical trial planned for mid 2026. She is currently moving forward with the development of a new recombinant BCG strain as an improved vaccine against tuberculosis for both humans and bovines. She has been director of the Biotechnology Center and of the Vaccine Development Laboratory, vice president of the Butantan Foundation, and member of the Steering Committee of the Vaccine Manufacturing Network in Developing Countries (DCVMN) and of the National Technical Commission on Biosafety (CTNBio). She is currently member of the Academic Management Board of the Erasmus Mundus's Leading International Vaccinology Education (LIVE) and of the Brazilian TB Network. She has recently joined as member of the Scientific Committee of Biominas, a company dedicated to promoting innovation in bio, and member of the Scientific Advisory Committee of the Coalition for Pandemic Preparedness and Innovation (CEPI).